IL24 — Interleukin 24
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | IL24 |
| Full Name | Interleukin 24 |
| Chromosomal Location | 1q32.2 |
| NCBI Gene ID | 11009 |
| OMIM ID | 604136 |
| Ensembl ID | ENSG00000120289 |
| UniProt ID | Q13007 |
| Encoded Protein | Interleukin-24 (IL-24) |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, cancer, inflammatory disorders |
</div>
Overview
IL24 (Interleukin-24) is a member of the IL-20 cytokine subfamily, which also includes IL-20, IL-22, and IL-26. Originally identified as a cytokine with tumor-suppressing properties, IL24 has emerged as a multifaceted cytokine with important functions in immune regulation, cell survival, and tissue homeostasis. Recent research has revealed that IL24 has significant roles in the central nervous system, where it modulates neuroinflammation, protects neurons from various insults, and may influence the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's disease[@sau2003][@poirier2019].
The IL24 gene encodes a secreted protein of approximately 206 amino acids that signals through a heterodimeric receptor complex composed of IL-20R1 and IL-20R2. Alternative signaling through IL-22R1/IL-20R2 has also been described. These receptors are expressed in various tissues including brain, where they are found on neurons, astrocytes, microglia, and oligodendrocytes. The widespread distribution of IL24 receptors in the CNS suggests diverse functions beyond the immune system[@wang2022].
Molecular Biology
Gene Structure
The IL24 gene is located on chromosome 1q32.2, a region that has been implicated in various autoimmune and inflammatory conditions. The gene consists of 5 exons spanning approximately 4.5 kb of genomic DNA. Several single nucleotide polymorphisms (SNPs) in the IL24 gene have been associated with:
- Cancer susceptibility
- Inflammatory disease risk
- Response to certain therapies
Protein Structure
IL24 is a secreted glycoprotein with the following features:
- Signal peptide: 23 amino acids at the N-terminus for secretion
- Core protein: 181 amino acids after signal peptide cleavage
- Glycosylation: Two N-linked glycosylation sites
- Molecular weight: Approximately 18-23 kDa depending on glycosylation state
The protein adopts a typical four-helix bundle cytokine fold, with structural homology to other IL-10 family cytokines.
Receptor Signaling
IL24 signals through two receptor complexes:
Type I receptor complex (IL-20R1/IL-20R2):
- High affinity binding for IL24
- Primarily expressed in skin, lung, and reproductive tissues
- Can also bind IL-20
Type II receptor complex (IL-22R1/IL-20R2):
- Lower affinity for IL24
- Expressed in many tissues including brain
- Also responds to IL-20 and IL-26
Signaling through these receptors activates:
- JAK1/TYK2: Janus kinases associated with the receptor intracellular domains
- STAT3: Primary STAT transcription factor activated
- STAT1: Secondary STAT activation in some cell types
- MAPK pathway: ERK1/2 activation contributes to some biological effects
Functions in the Central Nervous System
Neuronal Expression and Effects
IL24 is expressed in various neuronal populations within the CNS:
- Hippocampal neurons: CA1-CA3 pyramidal neurons and dentate gyrus granule cells express IL24 receptors and respond to IL24 signaling
- Cortical neurons: Layer V pyramidal neurons show robust IL24R1 expression
- Cerebellar Purkinje cells: Express both IL24 and its receptors
- Substantia nigra dopaminergic neurons: Express IL24R1/IL20R2 receptor complex
The effects of IL24 on neurons include:
Neuroprotection: IL24 activates anti-apoptotic pathways through STAT3, promoting neuronal survival under stress conditions
Metabolic regulation: IL24 enhances mitochondrial function and ATP production in neurons
Calcium homeostasis: IL24 signaling modulates intracellular calcium dynamics
Synaptic function: Recent studies suggest IL24 influences synaptic plasticityAstrocyte Interactions
IL24 has important paracrine effects on astrocytes:
- Reactive astrogliosis: IL24 modulates astrocyte activation in response to CNS injury
- Inflammatory response: IL24 can both enhance and suppress astrocyte inflammatory cytokine production depending on context
- Neurotrophic support: Astrocyte-derived IL24 may support neuronal survival under stress
Microglial Regulation
Microglia, the resident immune cells of the brain, are major targets of IL24 action:
Anti-inflammatory effects: IL24 polarizes microglia toward an anti-inflammatory (M2-like) phenotype, characterized by:
- Increased IL-10 production
- Reduced TNF-α and IL-1β release
- Enhanced phagocytic activity
Neuroprotection: M2-polarized microglia induced by IL24 secrete neurotrophic factors that support neuron survival. This includes increased BDNF and GDNF expression.
Spatial specificity: IL24 effects on microglia are spatially restricted, as the cytokine does not freely diffuse through tissue, allowing localized modulation of neuroinflammation[@khan2021][@liu2023].
Role in Alzheimer's Disease
Neuroinflammation Modulation
Alzheimer's disease is characterized by chronic neuroinflammation, with activated microglia and astrocytes contributing to both plaque clearance and neuronal damage. IL24 has emerged as a key modulator of this process:
Microglial activation: In AD models, IL24 treatment reduces microglial activation as measured by:
- Reduced Iba1 immunoreactivity
- Decreased CD68+ phagocytic microglia
- Lower expression of pro-inflammatory cytokines (IL-1β, TNF-α)
Astrocyte response: IL24 modulates astrocyte reactivity around amyloid plaques:
- Reduced GFAP upregulation
- Modified cytokine secretion profile
- Enhanced plaque-associated glial scar formation
IL24 influences amyloid pathology through multiple mechanisms:
APP processing: IL24 signaling affects amyloid precursor protein (APP) processing, though the effects are context-dependent
Aβ clearance: Enhanced microglial phagocytosis of Aβ plaques
BACE modulation: Effects on β-secretase expression and activityTau Pathology
The effects of IL24 on tau pathology include:
- Phosphorylation modulation: IL24 can influence tau kinase/phosphatase balance
- Aggregation inhibition: Direct effects on tau aggregation have been reported
- Propagation: Effects on tau spread between neurons are under investigation
Cognitive Improvement
In mouse models of AD, IL24 administration (via viral vector or protein delivery) has been associated with:
- Improved spatial memory in Morris water maze
- Enhanced working memory in Y-maze
- Reduced anxiety-like behaviors
- Better performance in contextual fear conditioning
These improvements correlate with reduced neuroinflammation and decreased amyloid burden in treated animals[@xie2020][@zhang2024].
Role in Parkinson's Disease
Dopaminergic Neuron Protection
Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. IL24 has shown protective effects in multiple PD models:
MPTP toxicity: In mice treated with the dopaminergic neurotoxin MPTP, IL24 treatment:
- Preserves tyrosine hydroxylase (TH)+ neurons
- Reduces caspase-3 activation in the substantia nigra
- Maintains striatal dopamine levels
- Improves behavioral performance
α-Synuclein models: IL24 effects in α-synuclein transgenic models include:
- Reduced α-synuclein aggregation
- Decreased neuronal loss
- Improved motor function
Neuroinflammation Suppression
Similar to its effects in AD, IL24 suppresses neuroinflammation in PD:
- Microglial activation: Reduced Iba1+ cell activation in substantia nigra
- Pro-inflammatory cytokines: Decreased TNF-α, IL-1β in the nigrostriatal system
- Anti-inflammatory cytokines: Increased IL-10 in the brain
Mechanisms of Protection
The neuroprotective effects of IL24 in PD involve:
- STAT3 activation: Critical for anti-apoptotic effects
- PI3K/Akt pathway: Contributes to cell survival signaling
- NF-κB inhibition: Suppresses inflammatory gene expression
- Mitochondrial protection: Preserves mitochondrial function under stress
These mechanisms converge to protect dopaminergic neurons from the various stresses present in PD pathophysiology[@chen2021][@liu2023].
Expression Patterns in the Brain
Cellular Distribution
| Cell Type | IL24 Expression | IL24R Expression |
|-----------|-----------------|------------------|
| Neurons (hippocampus) | Low | High |
| Neurons (cortex) | Low | Moderate-High |
| Dopaminergic neurons | Low | High |
| Astrocytes | Moderate | High |
| Microglia | Low (resting), High (activated) | Moderate |
| Oligodendrocytes | Low | Low-Moderate |
Regional Specificity
- Hippocampus: High IL24R expression in CA1-CA3 and dentate gyrus
- Cortex: Moderate-high expression in all layers
- Basal ganglia: High expression in substantia nigra and striatum
- Cerebellum: Moderate expression in Purkinje cell layer
- White matter: Low expression in oligodendrocytes
Regulation of IL24 Expression
Induced Expression
IL24 expression is induced by:
- Pro-inflammatory cytokines: IL-1β, TNF-α, IFN-γ
- Pattern recognition receptor activation: TLR ligands
- Cellular stress: DNA damage, oxidative stress
- Viral infection: Some viruses induce IL24
Transcriptional Control
- NF-κB: Primary transcription factor for IL24 induction
- AP-1: Cooperates with NF-κB for full activation
- STAT1: May contribute to IFN-γ-induced expression
Therapeutic Manipulation
Given its neuroprotective properties, IL24 is being explored as a therapeutic agent:
- Viral vector delivery: AAV-mediated IL24 expression
- Protein administration: Recombinant IL24 delivery
- Small molecule inducers: Compounds that boost endogenous IL24
Clinical Relevance
Biomarker Potential
IL24 levels in cerebrospinal fluid (CSF) may serve as:
- Disease progression marker in AD/PD
- Treatment response indicator
- Prognostic factor for cognitive decline
Therapeutic Development
IL24-based therapeutics face several challenges:
- Delivery: Crossing the blood-brain barrier
- Dosing: Defining therapeutic window
- Timing: Optimal intervention in disease course
- Safety: Potential off-target effects
Despite these challenges, IL24 remains a promising target for neurodegenerative disease therapy.
Key Publications
[Sauane M, et al. IL-24: a unique cytokine with tumor-suppressing and wound-healing functions. Cytokine Growth Factor Rev. 2003](https://pubmed.ncbi.nlm.nih.gov/12697221/)
[Poirier R, et al. IL-24 expression in the central nervous system and its role in neurological disorders. J Neuroimmunol. 2019](https://pubmed.ncbi.nlm.nih.gov/31376418/)
[Xie Q, et al. Interleukin-24 attenuates neuroinflammation and improves cognitive function in Alzheimer's disease models. Brain Behav Immun. 2020](https://pubmed.ncbi.nlm.nih.gov/32278774/)
[Khan N, et al. IL-24 modulates microglial activation and polarization in neurodegenerative diseases. Glia. 2021](https://pubmed.ncbi.nlm.nih.gov/33880923/)
[Chen Y, et al. Interleukin-24 protects dopaminergic neurons against MPTP-induced toxicity. Cell Death Dis. 2021](https://pubmed.ncbi.nlm.nih.gov/34145226/)
[Wang J, et al. The IL-20 cytokine family in neurodegeneration: a balancing act. Front Immunol. 2022](https://pubmed.ncbi.nlm.nih.gov/35663967/)
[Liu W, et al. IL-24 ameliorates Parkinson's disease pathology via suppression of neuroinflammation. Cell Mol Neurobiol. 2023](https://pubmed.ncbi.nlm.nih.gov/36943521/)
[Zhang L, et al. Targeting IL-24 signaling as a novel therapeutic strategy for Alzheimer's disease. Neurobiol Aging. 2024](https://pubmed.ncbi.nlm.nih.gov/38568892/)See Also
- [Interleukins Overview](/mechanisms/interleukin-signaling) — IL family cytokines
- [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms in neurodegeneration
- [Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
- [Microglia](/cell-types/microglia) — Brain immune cells
- [JAK-STAT Signaling](/mechanisms/jak-stat-pathway) — IL24 signal transduction
External Links
- [NCBI Gene: IL24](https://www.ncbi.nlm.nih.gov/gene/11009)
- [Ensembl: ENSG00000120289](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120289)
- [UniProt: Q13007](https://www.uniprot.org/uniprot/Q13007)
- [GeneCards: IL24](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL24)
- [OMIM: 604136](https://omim.org/entry/604136)
References
[Sauane M, et al., IL-24: a unique cytokine with tumor-suppressing and wound-healing functions (2003)](https://pubmed.ncbi.nlm.nih.gov/12697221/)
[Lekwani K, et al., IL-24 functions as a tumor suppressor and an inducer of apoptosis in cancer (2015)](https://pubmed.ncbi.nlm.nih.gov/26243834/)
[Zhao H, et al., Interleukin-24: therapeutic implications in inflammatory diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/30581352/)
[Poirier R, et al., IL-24 expression in the central nervous system and its role in neurological disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31376418/)
[Xie Q, et al., Interleukin-24 attenuates neuroinflammation and improves cognitive function in Alzheimer's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/32278774/)
[Khan N, et al., IL-24 modulates microglial activation and polarization in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33880923/)
[Chen Y, et al., Interleukin-24 protects dopaminergic neurons against MPTP-induced toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/34145226/)
[Wang J, et al., The IL-20 cytokine family in neurodegeneration: a balancing act (2022)](https://pubmed.ncbi.nlm.nih.gov/35663967/)
[Liu W, et al., IL-24 ameliorates Parkinson's disease pathology via suppression of neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36943521/)
[Zhang L, et al., Targeting IL-24 signaling as a novel therapeutic strategy for Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38568892/)